Biogen (BIIB) exec says they expect 2026 sales for MS products, excluding Vumerity to decline by the mid teen percentages
Importance
Level 1
#BIOGEN IDEC INC#BIIB.US#MORGAN STANLEY#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#INVESTMENT BANKING & BROKERAGE#BIOTECHNOLOGY (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#MS#US EQUITIES